**DOCKET NO.:** 34092-001 [P-2942-US] PATENT

Application No.: 10/528,496
Office Action Dated: June 22, 2010

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

1. (Original) A compound that inhibits complement activation, which comprises a peptide having a sequence:

Xaa1 - Cys - Val - Xaa2 - Gln - Asp - Trp - Gly - Xaa3 - His - Arg - Cys - Xaa4 (SEQ ID NO:15);

wherein:

Xaa1 is Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu or a dipeptide comprising Gly-Ile;

Xaa2 is Trp or a peptidic or non-peptidic analog of Trp;

Xaa3 is His, Ala, Phe or Trp;

Xaa4 is L-Thr, D-Thr, Ile, Val, Gly, or a tripeptide comprising Thr-Ala-Asn, wherein a carboxy terminal –OH of any of the L-Thr, D-Thr, Ile, Val, Gly or Asn optionally is replaced by –NH<sub>2</sub>; and

the two Cys residues are joined by a disulfide bond.

- 2. (Original) The compound of claim 1, wherein Xaa1 is Ac-Ile.
- 3. (Original) The compound of claim 1, wherein Xaa3 is Ala.
- 4. (Original) The compound of claim 1, wherein Xaa2 is an analog of Trp comprising a substituted or unsubstituted bicyclic aromatic ring component or two or more substituted or unsubstituted monocyclic aromatic ring components.
- 5. (Currently amended) The compound of claim 4, wherein the analog of Trp is selected from the group consisting of 2-naphthylalanine 2-naphthylalanine, 1-naphthylalanine 1-naphthylalanine, 2-indanylglycine carboxylic acid, dihydrotryptophan and benzoylphenylalanine.
- 6. (Currently amended) The compound of claim 1, wherein Xaa1 is Ac-Ile, Xaa2 is Trp or an analog of Trp comprising a substituted or unsubstituted indole, naphthyl or dibenzoyl component, Xaa3 is Ala and Xaa4 is <u>L-Thr or D-Thr, wherein the carboxy terminal --OH of the L-Thr or D-Thr optionally is replaced by -NH<sub>2</sub> L threonine or D-threonine.

  Page 4 of 7</u>

**PATENT** 

**DOCKET NO.:** 34092-001 [P-2942-US]

**Application No.:** 10/528,496

Office Action Dated: June 22, 2010

7. (Original) The compound of claim 6, having a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

- 8. (Original) The compound of claim 1, wherein Xaa1 is a dipeptide Gly-Ile, and Xaa 4 is a tripeptide Thr-Ala-Asn.
- 9. (Original) The compound of claim 8, comprising a peptide having SEQ ID NO:14.
- 10 17. (Canceled)